



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/01/16
LAST REVIEW DATE: 8/15/19
LAST CRITERIA REVISION DATE: 8/15/19
ARCHIVE DATE:

POMALYST® (pomalidomide) oral capsule

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "Description" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "Criteria" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at www.azblue.com/pharmacy.

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the [request form](#) in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to Pharmacyprecert@azblue.com. **Incomplete forms or forms without the chart notes will be returned.**

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/01/16
LAST REVIEW DATE: 8/15/19
LAST CRITERIA REVISION DATE: 8/15/19
ARCHIVE DATE:

POMALYST® (pomalidomide) oral capsule

Criteria:

- **Criteria for initial therapy:** Pomalyst (pomalidomide) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in cancer or is in consultation an Oncologist
 2. Individual is 18 years of age or older
 3. A confirmed diagnosis of **ONE** of the following:
 - Multiple myeloma that has progressed on or within 60 days of completion of at least **two prior therapies** that included lenalidomide with a proteasome inhibitor such as Velcade (bortezomib), Kyprolis (carfilzomib) or Ninlaro (ixazomib)
 - Other request for a specific oncologic direct treatment use that is found and listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A
 4. Pomalyst will be used in combination with dexamethasone
 5. **ALL** of the following baseline tests have been completed before initiation of treatment with continued monitoring as clinically appropriate:
 - Complete blood count
 - Liver function tests
 6. There are **NO** contraindications:
 - Contraindications include:
 - Pregnancy

Initial approval duration: 6 months

- **Criteria for continuation of coverage (renewal request):** Pomalyst (pomalidomide) is considered *medically necessary* and will be approved with documentation of **ALL** of the following:
1. Individual continues to be seen by a physician specializing in cancer or is in consultation an Oncologist
 2. Individual's condition responded while on therapy
 - Response is defined as:
 - No evidence of disease progression
 - Documented evidence of efficacy, disease stability and/or improvement
 3. Individual has been adherent with the medication

PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/01/16
LAST REVIEW DATE: 8/15/19
LAST CRITERIA REVISION DATE: 8/15/19
ARCHIVE DATE:

POMALYST® (pomalidomide) oral capsule

4. Individual has not developed any contraindications or other significant level 4 adverse drug effects that may exclude continued use, such as:
- Venous thromboembolism (DVT, PE)
 - Arterial thromboembolism (MI, CVA)
 - Allergic reaction (angioedema, skin exfoliation, bullae)
 - Liver failure
 - Neuropathy
 - Tumor lysis syndrome
5. There are no significant interacting drugs

Renewal duration: 12 months

Description:

Pomalyst (pomalidomide) is a thalidomide analogue, **used in combination with dexamethasone, is indicated for the treatment of patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression** on or within 60 days of completion of the last therapy.

Pomalidomide is an immunomodulatory agent with antineoplastic activity. In *in vitro* cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation of lenalidomide-resistant MM cell lines and synergized with dexamethasone in both lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell apoptosis. Pomalidomide enhanced T-cell and natural killer (NK) cell-mediated immunity and inhibited production of pro-inflammatory cytokines (e.g., TNF- α and IL-6) by monocytes.

Use of Pomalyst (pomalidomide) is subject to a Risk Evaluation and Mitigation Strategies (REMS) program that requires provider, patient, and dispensing pharmacy be enrolled into the program. Only providers and Pharmacies enrolled into the REMS may prescribe and dispense the drug, respectively, to individuals who are also in the program. A REMS program attempts to manage known or potentially serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) for some drugs to ensure that the benefits of a drug outweigh its risks.

Definitions:

Pomalyst (pomalidomide) REMS items

- Enrollment and agreement information
- Treatment initiation information
- Treatment maintenance information
- Pharmacy requirements and responsibilities



PHARMACY COVERAGE GUIDELINES
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 1/01/16
LAST REVIEW DATE: 8/15/19
LAST CRITERIA REVISION DATE: 8/15/19
ARCHIVE DATE:

POMALYST® (pomalidomide) oral capsule

Counseling on contraception and avoidance of pregnancy
Pregnancy testing in females of childbearing potential
Counseling on serious risks, warnings, and precautions and safe use

Proteasome inhibitors:

Velcade (bortezomib)
Kyprolis (carfilzomib)
Ninlaro (ixazomib)

Resources:

Pomalyst. Package Insert. Revised by manufacturer 04/2015. Accessed 08-04-2015.

Pomalyst. Package Insert. Revised by manufacturer 06/2016. Accessed 07-22-2016, 08-24-2017.

Pomalyst. Package Insert. Revised by manufacturer 05/2018. Accessed 07-19-2018.

NCCN Clinical Practice Guidelines in Oncology: Multiple myeloma. Version 3.2017, November 28, 2016.
https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

NCCN Clinical Practice Guidelines in Oncology: Multiple myeloma. Version 1.2019, July 20, 2018.
https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

UpToDate: Treatment of refractory multiple myeloma. Current through Aug 2017. https://www.uptodate-com.mwu.idm.oclc.org/contents/treatment-of-relapsed-or-refractory-multiple-myeloma?source=search_result&search=multiple%20myeloma&selectedTitle=4~150#H22

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.
